Drugs / HLA-A2 restricted synthetic tumor antigen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01795313 | Aug 2012 → Dec 2025 | ependymoma | James Felker | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLA-A2 restricted synthetic tumor antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01795313 ↗ |
| Modality | Vaccine | “This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod” NCT01795313 ↗ |